KRAS and neuroendocrine carcinoma: We observed no responders among BRAF V600E mutated NEC (n = 9), compared to 41% among BRAF wild type (n = 101; p = 0.016) and double-wild type BRAF/KRAS had higher RR (45 vs 22%, p = 0.023) compared to NEC harbouring either mutation.